BioSpace News Archive

Covetrus®, a global leader in animal-health technology and services, announced that Link Welborn, DVM, DABVP, the company’s Chief Veterinary Officer, will assume an expanded role and additional responsibilities in 2024.

NeuroLogica Corp. announces its OmniTom Elite PCD has received an Innovative Technology designation from Vizient, Inc., the largest provider-driven healthcare performance improvement company in the country.

Endovascular Engineering (“E2"), a medical device company focused on the development and deployment of groundbreaking clot removal technologies that target venous thromboembolism (VTE), announced today FDA Investigational Device Exemption (IDE) approval for its ENGULF US pivotal trial.

PharmAlliance, a diversified pharmaceutical and life sciences services provider, is pleased to announce its acquisition of Monitorforhire, a robust business that leverages an online system matching clinical research monitors with sponsors.

A recent Position Paper from the American College of Clinical Pharmacology® entitled “Inclusion of Obese Participants in Drug Development: Reflections on the Current Landscape and a Call for Action” was published in The Journal of Clinical Pharmacology.

For over 60 years, Rockland has been providing antibodies, assays, and supporting reagents to accurately reflect the quality of biopharmaceutical products from early- to late-stage bioprocessing.

BioGX, a leading global provider of easy molecular diagnostic solutions, is pleased to announce the test menu expansion support to Departments of Health with the addition of its Candida auris assay.

Biosenta Inc. (CSE: ZRO) (“Biosenta” or the “Company”) announces that it has entered into an agreement with Oak Hill Financial Inc. (“Oak Hill”) to provide business

In a landmark development for the orthopedic implant industry, Extremity Medical LLC, a pioneering medical engineering firm, has announced a strategic relationship with Henry Schein, Inc., a global healthcare solutions company.

XOMA Corporation, the biotech royalty aggregator, announced that based upon the U.S. Food and Drug Administration’s acceptance of Zevra Therapeutics’ New Drug Application for arimoclomol, an orally-delivered, first-in-class therapy for Niemann-Pick disease type C, XOMA will make a $1 million milestone payment to LadRx.